Ultromics raises $55M in funding round Ultromics has raised $55 million in series C financing that will go toward its AI-powered echocardiography software portfolio.

www.auntminnie.com/clinical-new...

Dr. Masri from #ACC.25. Responders analysis - acoramidis vs placebo for improving NYHA class from the ATTRibute-CM. #ACC25 #CardioSky #Cardiology

ASE experts connect with industry partners to drive advances in the field like #Strain, #3DEcho, and #ArtificialIntelligence while focusing on disease diagnosis in #HCM, #Amyloidosis, #ValveDisease, and more!

#ASEIRT #PartnersInInnovation #HeartofASE #ASEMemberDay #EchoFirst

The pivotal ATTR-ACT trial showed tafamadis ⬇️ mort rates in patients w/ATTR-CM. What about real world data?

🌍THOAS data confirms the mort benefit w/⬆️ survival rates compared to ATTR-ACT trial. Early diagnosis and treatment is 🔑 in amyloid CM 🫀

🔗 bit.ly/4imXPCw

New ATTR-CM therapies shine: Pfizer’s Tafamidis cuts mortality 13%, Alnylam’s Vutrisiran slashes CV events 28%, Ionis/AstraZeneca’s Eplontersen in trials, BridgeBio’s Acoramidis boosts survival to 81%. Early Dx is key—EchoGo’s AI interprets echos to spot it fast. CRISPR looms big! @ultromics.com

🧠 Can Imaging Be a Surrogate Endpoint in Amyloidosis Trials?

A recent JACC:CVI review by Dorbala et al. highlights the role of imaging biomarkers in clinical trials for amyloidosis.

www.jacc.org/doi/abs/10.1...

#HeartMonth is a great time to get a cardiac risk assessment & know if you are at risk for heart disease. 80% of heart disease is preventable but we don’t often screen women. Heart disease is the #1 killer of women. Lack of awareness is a close second.

#GoRedforWomen #CVPrev #CardioSky

Heart disease in women is far too often misdiagnosed or dismissed

A (not so) shocking 84% of female cardiologists surveyed reported treating women whose symptoms were ignored or misdiagnosed

This is disgraceful. Advocate for better awareness.
#CVprev #Cardiosky
#HeartAndSoul

EchoGo® Heart Failure was developed with Mayo Clinic.
Patricia A. Pellikka, MD shares her views on the impact of our AI platform in detecting heart failure patients. Learn more about how EchoGo® Heart Failure supports #HeartFailure detection: www.ultromics.com/products/ech... #CardioSky #MedSky

EchoGo® Amyloidosis is the first AI screening tool to help detect Cardiac #Amyloidosis using #EchoFirst. Seamlessly integrating into clinical workflows, it supports timely identification and intervention. 👉 www.ultromics.com/products/ech... #MedSky #CardioSky

Welcome immigrants from X interested in science to the friendlier skies of @bsky.app, as documented by a new @nature.com survey (but you already knew that 😉)
"Bluesky is much better for science. There is much less toxicity, misinformation, and distractions."
www.nature.com/articles/d41...

In the European Heart Journal, we report a novel paradigm for predicting HF risk.

AI applied to a single ECG image. Without risk scores or other testing.

Led by @lovedeepdhingra.bsky.social @cardslab.bsky.social

@yaleschoolofmed.bsky.social

🔗 academic.oup.com/eurheartj/ad...

Prime Minister sets out blueprint to turbocharge AI Artificial intelligence will deliver a decade of national renewal, as part of a new plan announced today (13 January 2025).

www.gov.uk/government/n...

❓ Test your knowledge:

Cardiac #Amyloidosis is challenging to diagnose, often requiring a high degree of clinical suspicion. Early recognition of red flags, including non-cardiac indicators, is critical for timely diagnosis and effective treatment. #CardioSky #MedSky

We’re excited to share our latest research & innovation at several events this year. Ultromics is transforming cardiology with advanced AI that supports #HFpEF and Cardiac #Amyloidosis detection. Upcoming events: www.ultromics.com/about/events #EchoGo #MedSky #CardioSky

Prime Minister sets out blueprint to turbocharge AI Artificial intelligence will deliver a decade of national renewal, as part of a new plan announced today (13 January 2025).

www.gov.uk/government/n...

Detecting HFpEF early is critical so patients can benefit from these innovative treatments. #SGLT2 inhibitors are a breakthrough treatment for HFpEF. However, many patients are undiagnosed. EchoGo® Heart Failure uses advanced AI to detect #HFpEF from a single routine echo. Learn more: ultromics.com

EchoGo® Heart Failure is eligible for reimbursement in both inpatient & outpatient settings & includes
#HFpEF & Cardiac Amyloidosis detection to aid care in #HeartFailure.

💰 Inpatient: NTAP XXE2X19 – Up to $1,023.75
💰 Outpatient: CPT 0932T – $299.91

👉https://www.ultromics.com/about/reimbursement

Erin Michos, MD: HFpEF in Women and Sex-Specific Therapeutic Approaches Erin Michos, MD examines unique HFpEF mechanisms for women and implications for sex-specific treatment.

Here at the #WCIRDC2024 conference where I presented in #HFpEF and sex specific considerations for women. I shared a summary of this with #HCPLive . #CardioSky #WomensHeartHealth

www.hcplive.com/view/erin-mi...

2024 was a blast in cardiovascular imaging congresses led by EACVI. Be ready for #EACVI2025:
📍Vienna
📅11-13 Dcember
👨‍👩‍👦‍👦#EuroeEcho, #EuroCMR and #ICNC-CT together
Help us to shape the programme and be part of it
👉escardio.formstack.com/forms/eacvi_2025_call_fo... #cardiosky

Hello #Medsky #CardioSky

The ESC is now on Bluesky🙂

We aim to bring you here the latest in cutting-edge cardiovascular science, from all ESC resources, including the successful #ESCTVToday CV news programme. We equally aim to bring you updates from all ESC communities and to bring you altogether.

Ultromics obtains Breakthrough Device FDA clearance for its Cardiac Amyloidosis screening device through the Total Product Lifecycle Advisory Program Ultromics granted FDA Breakthrough Device Designation for its Amyloidosis device

www.ultromics.com/press-releas...